Southern Acids (M) Bhd (5134) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Southern Acids (M) Bhd stock MYR 4.65, price MYR 3.00, upside +55.0%, quality 63 out of 100. Rating: strongly undervalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 2.48 MYR – 3.89 MYR · fair‑value band 4.15 MYR – 5.68 MYR · the 3.00 MYR price screens below the 4.65 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Southern Acids (M) Bhd in your weekly email
Every Wednesday you see whether Southern Acids (M) Bhd is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Southern Acids (M) Berhad, an investment holding company, engages in the manufacture and trading of oleochemical products in Malaysia, Indonesia, Asia, Europe, the United States, and internationally.
Show moreShow less
The company operates through four segments: Oleochemical Manufacturing, Milling & Cultivation, Investments & Services, and Healthcare Services. It offers fatty acids and glycerine for use in various applications, including personal care, cleaning agents, cosmetic, pharmaceutical, and food products.
It is also involved in the processing of fresh fruit bunches into crude palm oil and palm kernel, as well as oil palm cultivation activities.
In addition, it operates private hospital in Klang for the provision of cardiology, hand and microsurgery, nephrology, neurosurgery, orthopaedic surgery, obstetrics and gynaecology, radiotherapy, oncology services, cancer, fertility, cardiac care, and E.N.T. head and neck surgery.
Further, it provides plantation; administrative; overhead conveyor goods loading services; warehousing; and port cargo handling, as well as develops properties and leases hospital building. Southern Acids (M) Berhad was incorporated in 1980 and is headquartered in Klang, Malaysia.
Stock analysis
Southern Acids (M) Bhd (5134) currently trades at 3.00 MYR, while our model-based Fair Value estimate is 4.65 MYR, implying the stock looks roughly 35% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 5.83 MYR per share, and 10 of the 12 models we run sit above the 3.00 MYR price.
Bear case: the Asset-Based group reads lowest at 3.59 MYR, and 2 of the 12 models stay below the price. Data coverage for this calculation is low.
Scenario range: 4.15 MYR (bear) to 5.68 MYR (bull), the price of 3.00 MYR sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 63/100 (solid quality), in the Industrials sector.
Mixed Growth: Spin-off in 2026: revenue and profit before it include the divested business. Growth is measured afresh from 2026.
Southern Acids (M) Bhd reported revenue of 919M MYR in FY2026 versus 1.2B MYR in FY2022, a compound −6.0%/yr. Reported net income was 37.4M MYR in FY2026, compounding −20.7%/yr from FY2022.
Key figures
Market cap 411M MYR (≈ $101M) Micro · P/E ratio 7.9 · P/S ratio 0.44 · EPS (TTM) 0.3800 MYR · Dividend yield 1.7% · Net margin 5.5% · Return on equity 7.7% · Return on assets (EBIT) 8.5% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 43 out of 100 (low confidence).
What moves the price
The share trades about 13% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Industrials peers we cover trades at 8% fair-value upside, at 55%, 5134 screens cheaper than that median.
Fair Value models
Bear4.15 MYRFair Value 4.65 MYRBull5.68 MYR
Price 3.00 MYR · Upside +55.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (0.2016 MYR per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2026: revenue and profit before it include the divested business. Growth is measured afresh from 2026.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.6%
Start year 2020 (pandemic). Over 10 years: +6.9% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in MYR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in MYR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+1.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.0%
Dividend (yield on the price)1.7%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.0.0% vs 3.7%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 8%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
The company could shrink this much every year for the next five years and today's price would still be justified.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Conglomerates · 304 stocks
Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score63 · Top 25%
Fair Value upside+55.0% · Above median
Profitability
Return on equity (12 months)7.7% · Above median
Return on assets3.7% · Above median
Net margin (12 months)5.5% · Below median
Operating margin (12 months)11.5% · Above median
Growth and dividend
Revenue growth (quarter YoY)4.3% · Below median
Dividend yield (12 months)1.7% · Below median
Valuation Multiplesvs Conglomerates median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Southern Acids (M) Bhd Fair Value". https://www.fairvalue-calculator.com/stock/5134
Frequently asked questions
Is Southern Acids (M) Bhd (5134) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 4.65 MYR versus a price of 3.00 MYR, about +55% upside (undervalued).
What is the fair value of 5134?
Our model-based fair value for Southern Acids (M) Bhd is 4.65 MYR (as of Nov 9, 2026), built from audited fundamentals. The current price: 3.00 MYR.
What is the quality score of 5134?
Southern Acids (M) Bhd has a Quality Score of 63/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Southern Acids (M) Bhd (5134)?
Our model-based price target is the fair value of 4.65 MYR (as of Nov 9, 2026) from 12 valuation models. Cautious scenario 4.15 MYR, optimistic scenario 5.68 MYR. It is a calculation from audited fundamentals, not an analyst target.
What is the Southern Acids (M) Bhd stock forecast for 2026?
Our models put fair value at 4.65 MYR, about +55% upside versus a price of 3.00 MYR (undervalued). Cautious scenario 4.15 MYR, optimistic scenario 5.68 MYR. The calculation is refreshed regularly with new filings.
What is the revenue of Southern Acids (M) Bhd (5134)?
Southern Acids (M) Bhd reported trailing-twelve-month revenue of about 943M MYR (latest available figure, as of Nov 9, 2026).
Does Southern Acids (M) Bhd pay a dividend?
Southern Acids (M) Bhd currently shows a dividend yield of 1.67% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Southern Acids (M) Bhd (5134) and when is the ex-dividend date?
Southern Acids (M) Bhd pays a dividend of 0.05 MYR per share a year, a dividend yield of 1.7%. The last ex-dividend date was Oct 15, 2026. A dividend has been paid every year since at least 1994. The payout ratio is 13.2% of earnings. Free cash flow covers the dividend 12.23 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Southern Acids (M) Bhd (5134)?
For today's price to be fair in a discounted-cash-flow model, Southern Acids (M) Bhd would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 12.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.4 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 5134 use?
Our models discount Southern Acids (M) Bhd at 12.6 %: a base by market capitalisation (micro), damped by beta 0.22, country premium for Malaysia. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Southern Acids (M) Bhd that is less than minus 40 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.6 %) and the same formula as our fair value.
How much growth has Southern Acids (M) Bhd (5134) delivered so far?
Over the past 5 years revenue at Southern Acids (M) Bhd grew +4.4 % a year. The price currently implies free-cash-flow growth of less than minus 40 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Southern Acids (M) Bhd (5134) growing?
The median revenue growth in the sector is +7.8 % a year. That is the yardstick for the growth priced into Southern Acids (M) Bhd (less than minus 40 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Southern Acids (M) Bhd (5134)?
The free-cash-flow yield on the price is 20.38 %: that much free cash flow Southern Acids (M) Bhd produces per unit of market value. When it exceeds the discount rate of our models (12.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Southern Acids (M) Bhd (5134)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Southern Acids (M) Bhd it is 4.65 MYR per share (as of Nov 9, 2026), against a price of 3.00 MYR. It is the blended result of 12 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit).
Is Southern Acids (M) Bhd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 5134 trades below its calculated fair value: price 3.00 MYR, fair value 4.65 MYR, a gap of about +55% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 5134?
No. The price is what the market pays today (3.00 MYR); the fair value is what the company's own numbers justify (4.65 MYR). For Southern Acids (M) Bhd the two are 1.65 MYR per share apart. That gap is exactly why we show both numbers side by side.
How much is Southern Acids (M) Bhd worth?
The market values Southern Acids (M) Bhd at about 411M MYR (market capitalisation, as of Nov 9, 2026). Per share that is 3.00 MYR; our models calculate a fair value of 4.65 MYR per share.
What do the bullish and bearish scenarios say about 5134?
Our models span a range for Southern Acids (M) Bhd: cautious scenario 4.15 MYR, base 4.65 MYR, optimistic 5.68 MYR per share (as of Nov 9, 2026, price 3.00 MYR). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 5134?
Southern Acids (M) Bhd trades at a price-to-earnings ratio of 7.9 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 4.65 MYR is built from several models across several years. Other multiples: P/B 0.5, P/S 0.4.
How solid is the balance sheet of Southern Acids (M) Bhd (5134)?
Balance-sheet figures for Southern Acids (M) Bhd (as of Nov 9, 2026): return on equity 7.7%. They feed the Quality Score of 63/100, which measures business quality independently of the share price.
How far is 5134 from its 52-week high?
Southern Acids (M) Bhd trades at 3.00 MYR, about 13% below its 52-week high of 3.45 MYR and 2% above the low of 2.95 MYR (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 4.65 MYR is for.
Which stocks are comparable to Southern Acids (M) Bhd?
From the same area (Industrials) we also value 3M Company, Honeywell International Inc, Swire Pacific Limited, SGH Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Southern Acids (M) Bhd stock attractive at the current price?
The data as of Nov 9, 2026: price 3.00 MYR, calculated fair value 4.65 MYR (+55%), Quality Score 63/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 5134 calculated?
We run Southern Acids (M) Bhd through 12 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of 4.65 MYR builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Southern Acids (M) Bhd currently trades 35% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Southern Acids (M) Bhd (5134)?
The closing price on Nov 6, 2026 was 3.00 MYR. Our model-based fair value is 4.65 MYR, about +55% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Southern Acids (M) Bhd right now?
The price is below even our cautious bear case (4.15 MYR). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (63/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Southern Acids (M) Bhd
How large is the market capitalisation of Southern Acids (M) Bhd (5134)?
The market capitalisation of Southern Acids (M) Bhd is 411M MYR (≈ $101M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Southern Acids (M) Bhd (5134)?
The price-to-sales ratio of Southern Acids (M) Bhd is 0.44 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Southern Acids (M) Bhd (5134)?
Earnings per share at Southern Acids (M) Bhd are 0.3800 MYR (price ÷ EPS = P/E 7.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Southern Acids (M) Bhd (5134)?
The dividend yield of Southern Acids (M) Bhd is 1.7% (payout 13.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Southern Acids (M) Bhd (5134)?
The net margin of Southern Acids (M) Bhd is 5.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Southern Acids (M) Bhd (5134)?
The return on equity (ROE) of Southern Acids (M) Bhd is 7.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Southern Acids (M) Bhd (5134)?
On an EBIT basis the return on assets of Southern Acids (M) Bhd is 8.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Southern Acids (M) Bhd (5134)?
The operating margin of Southern Acids (M) Bhd is 11.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Southern Acids (M) Bhd (5134)?
Revenue at Southern Acids (M) Bhd is growing +4.3% versus a year earlier (3y avg −5.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Southern Acids (M) Bhd (5134)?
Earnings per share at Southern Acids (M) Bhd are growing +380% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Southern Acids (M) Bhd in the live analysis
One click puts Southern Acids (M) Bhd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026